7월 29일 · 실적분석
실적분석
Amarin ($AMRN) Q2 2026 Earnings Analysis — Revenue Miss Overshadowed by Cost Cuts, International Demand, and Cash Flow, Driving Positive Market Reaction
AMRN Amarin 실적 요약Amarin ($AMRN) posted Q2 2026 net revenue of $42.2 million, down 42% year-over-year and below the $44.55 million consensus estimate. The bulk of the decline reflects a base effect: last year's Q2 included a $25 million recordati upfront that did not recur. GAAP net loss narrowed to roughly $7.7 million ($0.02 per common share loss), and the spotlight fell on the meaningful reduction in operating expenses, a third consecutive quarter of positive cash flow, and a 59% surge in partner-local demand globally. The company reiterated full-year international growth, maintained US market share, and guided to roughly 10% growth in year-end cash. The market is clearly prioritizing the improving fundamentals over the headline revenue decline.
Earnings Scorecard
▸ Revenue: $42.2 million (YoY -42%, estimate $44.55 million) ❌ Miss
▸ EPS (Earnings Per Share): GAAP net loss per common share of $0.02 (narrowed from a $0.03 loss YoY). Non-GAAP (Non-Generally Accepted Accounting Principles) net income per ADS (American Depositary Share) of $0.04. As a small-cap, consensus coverage is thin, so the comparison is best made on a YoY basis.
▸ Guidance: Maintained (qualitative) — full-year 2026 international market growth, maintained US Vascepa share, improved cost structure, continued positive cash flow, with year-end cash expected to grow roughly 10% versus prior year-end (no specific revenue or EPS figures provided)
▸ Stock Reaction: +3.23% after-hours ($14.4) — as of 07-29 20:35 Korean Standard Time
The Positives
▸ Cost structure overhaul complete: Operating expenses of $27 million, a 59% reduction YoY; the $70 million annualized cost-savings plan has been completed
▸ Surging partner-local demand internationally: Partner-local demand up 59% YoY globally, with Europe +69% and cumulative China volumes +90%
▸ Cash and balance sheet strength: Cash of $314.6 million, no debt, third consecutive quarter of positive cash flow, and year-end cash expected to grow roughly 10%
Amarin is a biopharmaceutical company that sells the cardiovascular therapy Vascepa (US) and Vazkepa (Europe and others). The core takeaway from Q2 is closer to the "profit-and-loss impact of a business-model transition" than to the "top-line number." Following the Recordati partnership covering 59 European countries, direct selling costs dropped sharply, and operating expenses excluding restructuring charges fell by $16.6 million (-38%) YoY.
At the same time, separate from the revenue the company recognizes, partner-local end-demand has clearly expanded. In the US, IPE (icosapent ethyl) market share rose from 43% to 48%, and branded prescriptions grew 14%, holding ground despite generic competition. With the narrower net loss and rising cash position combined, the market appears to be reacting more to the path toward mid-term profitability than to the short-term revenue gap.
The Negatives
▸ Revenue missed both estimate and prior year: Net revenue of $42.2 million lagged the $44.55 million estimate and $72.7 million in the prior-year quarter
▸ Pressure on US product revenue: US product revenue of $32.2 million (-12%), with ongoing generic competition and net pricing pressure
▸ Still loss-making: GAAP operating loss of $12 million and net loss of roughly $7.7 million, weighed down by cost-of-goods-sold ratio
The biggest driver of the YoY revenue collapse is the absence of a roughly $25 million upfront licensing revenue recognized last year when the Recordati agreement took effect in Q2. Even adjusting for this one-time base effect, product revenue itself declined 16% and came in slightly below market expectations. In the US, prescription demand held up, but pricing pressure reduced total revenue, while Europe recognized revenue was soft YoY amid the partner-model transition.
Cost of goods sold (cost of products sold) actually rose 22%, narrowing gross-profit cushion. Operating expense savings narrowed the loss, but profitability has not yet been achieved. On a non-GAAP basis, results were near break-even and slightly positive on an ADS basis, but these are adjusted figures excluding litigation-related one-time costs and should not be confused with GAAP losses. Quarterly revenue can also fluctuate meaningfully depending on partner shipment timing.
What Management Said
Management's tone was close to "still early in the transition, but the direction is right." The CEO emphasized the trifecta of growing partner-network local demand internationally, the completion of large-scale cost reductions, and maintained US market standing, expressing confidence in the sustainable growth and profitability path. At the same time, the company noted that Barclays had been retained as exclusive financial advisor to explore additional avenues for enhancing shareholder value, leaving the door open to strategic options beyond a simple quarterly earnings recap.
The CFO put the spotlight on the lower cost baseline, three consecutive quarters of cash generation, and working-capital management from inventory reduction. The company did not provide specific quantitative quarterly or full-year revenue and EPS guidance, instead offering only qualitative operating and financial direction: international growth, maintained US volume, and roughly 10% year-end cash growth. The market appears to have read this as a "cost and cash-led stabilization story" rather than a "top-line guidance raise."
Market Reaction and What to Watch Next
The after-hours share price increase reflects the market interpreting the headline revenue decline as a one-time base effect and a business-model transition cost, while weighting the sharp operating expense reduction, rising cash, international partner-local demand, and expanding US share more heavily. Because this is a small-cap name, volatility can amplify when trading volume is thin, so confirming the durability of the reaction is safer done through the regular session and next quarter's print.
▸ Starting in Q3, when the European partner model becomes comparable on a year-over-year basis, it will be important to check how closely recognized revenue tracks with local demand growth.
▸ Watch whether US Vascepa maintains share and branded prescriptions amid generic pricing pressure, and whether net price declines further weigh on revenue.
▸ Looking toward year-end, key mid-term catalysts include whether cash approaches the company target of roughly 10% growth versus prior year-end and whether additional shareholder-return measures or business-development announcements materialize.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.
🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다